igfbp2  (OriGene)

Journal: Cancer Research Communications

Article Title: Age-Related Increases in IGFBP2 Increase Melanoma Cell Invasion and Lipid Synthesis

doi: 10.1158/2767-9764.CRC-23-0176

Figure Lengend Snippet: Aged fibroblasts secrete high levels of IGFBP2. A, Re-analysis of proteomics on CM from young and aged dermal fibroblasts, published in Kaur and colleagues , showing differentially expressed proteins between the two groups, in which red denotes increased expression in aged as compared with young, and blue denotes decreased expression. B, IGFBP2 ELISA analysis in young and aged human dermal fibroblast CM ( P = 0.0055). C, IGFBP2 staining in human melanoma skin reconstructs with young or aged donor-derived dermal fibroblasts. D, IGFBP2 staining in primary tumor tissue from young and aged C57BL6 mice. E, RPPA analysis of young and aged YUMM1.7 mouse tumor lysate for IGFBP2 expression ( P = 0.002). F, Pathway analysis of RPPA analysis of young and aged YUMM1.7 mouse tumor lysate. G, P-AKT (Ser473) staining of tumors in young and aged mice. H, Oil Red O staining of tumors in young and aged mice.

Article Snippet: Briefly, 500 μL of growth medium (20% FBS) was added to the bottom of each well, and a total of 2.5 × 10 4 cells resuspended in 250 μL of young conditioned media (CM) in the presence or absence of rIGFBP2 (150 ng/mL; 674-B2-025 from R&D Systems) or aged CM in the presence or absence of 5 mg/mL neutralizing IGFBP2 antibody (AF674 from R&D Systems) were seeded on top.

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Staining, Derivative Assay

Journal: Cancer Research Communications

Article Title: Age-Related Increases in IGFBP2 Increase Melanoma Cell Invasion and Lipid Synthesis

doi: 10.1158/2767-9764.CRC-23-0176

Figure Lengend Snippet: IGFBP2 induces fatty acid synthesis in melanoma cells. A, Western blot analysis of Igfbp2, phospho-Akt, total Akt and Hsp90 (loading control) from young and aged tumor lysate. Quantification of immunoblotting of Igfbp2 and phospho-Akt relative to Hsp90 loading control. B, Correlation analysis of IGFBP2 protein expression and p-AKT S473 expression from RPPA of melanoma PDX samples. C, Correlation analysis of IGFBP2 protein expression and p-AKT T308 expression from RPPA of melanoma PDX samples. D, Western blot analysis of melanoma cells (1205Lu) treated with recombinant IGFBP2 (100 ng/mL) at different times. Cells were probed for IGFBP2, phospho-AKT, total AKT, and HSP90 (loading control). E, Western blot analysis of IGFBP2 knockdown in aged fibroblasts. F, BODIPY (505/515) staining of human melanoma cells (1205Lu) cultured with aged fibroblast CM from fibroblasts transduced with empty vector (PLKO.1) or shRNA constructs (shIGFBP2). Quantification of BODIPY. G, BODIPY (505/515) staining of melanoma cells treated with CM from young fibroblasts treated with recombinant IGFBP2 (50 and 100 ng/mL). Quantification of BODIPY. H, RT-PCR of IGFBP2 expression in melanoma cells after treatment with young or aged CM. I, Western blot analysis of IGFBP2, P-AKT, total AKT, and HSP90 in melanoma cells transfected with either an empty vector control (CTRL) or IGFBP2 (IGFBP2 OE). J, BODIPY (493/503) staining of melanoma cells after transfection with either control or IGFBP2 constructs with quantification. GraphPad Prism 8 was used for plotting graphs and statistical analysis. Unpaired t test was performed.

Article Snippet: Briefly, 500 μL of growth medium (20% FBS) was added to the bottom of each well, and a total of 2.5 × 10 4 cells resuspended in 250 μL of young conditioned media (CM) in the presence or absence of rIGFBP2 (150 ng/mL; 674-B2-025 from R&D Systems) or aged CM in the presence or absence of 5 mg/mL neutralizing IGFBP2 antibody (AF674 from R&D Systems) were seeded on top.

Techniques: Western Blot, Control, Expressing, Recombinant, Knockdown, Staining, Cell Culture, Transduction, Plasmid Preparation, shRNA, Construct, Reverse Transcription Polymerase Chain Reaction, Transfection

Journal: Cancer Research Communications

Article Title: Age-Related Increases in IGFBP2 Increase Melanoma Cell Invasion and Lipid Synthesis

doi: 10.1158/2767-9764.CRC-23-0176

Figure Lengend Snippet: IGFBP2 increases melanoma cell migration and invasion. A, Wound healing assay of human melanoma cells (1205Lu, WM164) cultured with young or aged CM in the presence or absence of a neutralizing IGFBP2 antibody (5 mg/mL) or recombinant IGFBP2 (150 ng/mL). B, Matrigel invasion assay of melanoma cells (1205Lu, WM164) cultured with young and aged CM in the presence or absence of a neutralizing IGFBP2 antibody or recombinant IGFBP2. C, Melanoma cells (1205Lu) grown in 3D spheroids cultured with aged CM and young CM in the presence or absence of recombinant IGFBP2 (150 ng/mL) for 48 hours. GraphPad Prism 8 was used for plotting graphs and statistical analysis. Unpaired t test was performed.

Article Snippet: Briefly, 500 μL of growth medium (20% FBS) was added to the bottom of each well, and a total of 2.5 × 10 4 cells resuspended in 250 μL of young conditioned media (CM) in the presence or absence of rIGFBP2 (150 ng/mL; 674-B2-025 from R&D Systems) or aged CM in the presence or absence of 5 mg/mL neutralizing IGFBP2 antibody (AF674 from R&D Systems) were seeded on top.

Techniques: Migration, Wound Healing Assay, Cell Culture, Recombinant, Invasion Assay

Journal: Cancer Research Communications

Article Title: Age-Related Increases in IGFBP2 Increase Melanoma Cell Invasion and Lipid Synthesis

doi: 10.1158/2767-9764.CRC-23-0176

Figure Lengend Snippet: Igfbp2 increases melanoma tumor growth and metastasis in vivo . A, mCherry-tagged YUMM1.7 murine melanoma cells were grown in young (8 weeks old) C57BL6 mice. Tumor growth of young mice after i.p. treatment with 500 ng recombinant Igfbp2 or PBS (5 mice/group, treated i.p., 2 times a week, after tumors were palpable). B, IHC analysis of Igfbp2 in tumors from young mice treated with PBS or recombinant Igfbp2. C, Western blot analysis of tumor lysate from young mice treated with PBS and recombinant Igfbp2. Densitometry of phospho-AKT relative to HSP90 loading control. D, Tumor growth curve of YUMM1.7 melanoma cells subdermally injected in old (52 weeks old) mice treated i.p. with Igfbp2-neutralizing antibody (at a concentration of 1 mg/kg every day, n = 5) vs. an IgG control ( n = 5). E, IHC analysis of Igfbp2 staining in aged mice treated with either an IgG control or neutralizing Igfbp2 antibody. F, Protein expression analysis was performed on tumor lysate from aged mice treated with IgG or neutralizing Igfbp2 antibody. Quantification analysis of phospho-Akt and Fasn immunoblotting relative to Hsp90 loading control. G, Analysis of mCherry-positive cells in lungs of tumor-bearing aged mice treated with a neutralizing Igfbp2 antibody or IgG control. *, P < 0.05 student t test was used. GraphPad Prism 8 was used for plotting graphs and statistical analysis.

Article Snippet: Briefly, 500 μL of growth medium (20% FBS) was added to the bottom of each well, and a total of 2.5 × 10 4 cells resuspended in 250 μL of young conditioned media (CM) in the presence or absence of rIGFBP2 (150 ng/mL; 674-B2-025 from R&D Systems) or aged CM in the presence or absence of 5 mg/mL neutralizing IGFBP2 antibody (AF674 from R&D Systems) were seeded on top.

Techniques: In Vivo, Recombinant, Western Blot, Control, Injection, Concentration Assay, Staining, Expressing

Journal: Cancer Research Communications

Article Title: Age-Related Increases in IGFBP2 Increase Melanoma Cell Invasion and Lipid Synthesis

doi: 10.1158/2767-9764.CRC-23-0176

Figure Lengend Snippet: Aged fibroblasts secrete high levels of IGFBP2. A, Re-analysis of proteomics on CM from young and aged dermal fibroblasts, published in Kaur and colleagues , showing differentially expressed proteins between the two groups, in which red denotes increased expression in aged as compared with young, and blue denotes decreased expression. B, IGFBP2 ELISA analysis in young and aged human dermal fibroblast CM ( P = 0.0055). C, IGFBP2 staining in human melanoma skin reconstructs with young or aged donor-derived dermal fibroblasts. D, IGFBP2 staining in primary tumor tissue from young and aged C57BL6 mice. E, RPPA analysis of young and aged YUMM1.7 mouse tumor lysate for IGFBP2 expression ( P = 0.002). F, Pathway analysis of RPPA analysis of young and aged YUMM1.7 mouse tumor lysate. G, P-AKT (Ser473) staining of tumors in young and aged mice. H, Oil Red O staining of tumors in young and aged mice.

Article Snippet: Tumors were allowed to grow, and treatment with rIgfbp2 (674-B2-025 from R&D Systems), Igfbp2-neutralizing antibody (AF674 from R&D Systems), or IgG control (AB-105-C from R&D Systems) was administered. rIGFBP2 experiments: young mice were injected intraperitoneally with 500 ng of rIgfbp2 in 100 μL of PBS every 2 days until tumors reach a maximum of 2,000 mm 3 .

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Staining, Derivative Assay

Journal: Cancer Research Communications

Article Title: Age-Related Increases in IGFBP2 Increase Melanoma Cell Invasion and Lipid Synthesis

doi: 10.1158/2767-9764.CRC-23-0176

Figure Lengend Snippet: IGFBP2 induces fatty acid synthesis in melanoma cells. A, Western blot analysis of Igfbp2, phospho-Akt, total Akt and Hsp90 (loading control) from young and aged tumor lysate. Quantification of immunoblotting of Igfbp2 and phospho-Akt relative to Hsp90 loading control. B, Correlation analysis of IGFBP2 protein expression and p-AKT S473 expression from RPPA of melanoma PDX samples. C, Correlation analysis of IGFBP2 protein expression and p-AKT T308 expression from RPPA of melanoma PDX samples. D, Western blot analysis of melanoma cells (1205Lu) treated with recombinant IGFBP2 (100 ng/mL) at different times. Cells were probed for IGFBP2, phospho-AKT, total AKT, and HSP90 (loading control). E, Western blot analysis of IGFBP2 knockdown in aged fibroblasts. F, BODIPY (505/515) staining of human melanoma cells (1205Lu) cultured with aged fibroblast CM from fibroblasts transduced with empty vector (PLKO.1) or shRNA constructs (shIGFBP2). Quantification of BODIPY. G, BODIPY (505/515) staining of melanoma cells treated with CM from young fibroblasts treated with recombinant IGFBP2 (50 and 100 ng/mL). Quantification of BODIPY. H, RT-PCR of IGFBP2 expression in melanoma cells after treatment with young or aged CM. I, Western blot analysis of IGFBP2, P-AKT, total AKT, and HSP90 in melanoma cells transfected with either an empty vector control (CTRL) or IGFBP2 (IGFBP2 OE). J, BODIPY (493/503) staining of melanoma cells after transfection with either control or IGFBP2 constructs with quantification. GraphPad Prism 8 was used for plotting graphs and statistical analysis. Unpaired t test was performed.

Article Snippet: Tumors were allowed to grow, and treatment with rIgfbp2 (674-B2-025 from R&D Systems), Igfbp2-neutralizing antibody (AF674 from R&D Systems), or IgG control (AB-105-C from R&D Systems) was administered. rIGFBP2 experiments: young mice were injected intraperitoneally with 500 ng of rIgfbp2 in 100 μL of PBS every 2 days until tumors reach a maximum of 2,000 mm 3 .

Techniques: Western Blot, Control, Expressing, Recombinant, Knockdown, Staining, Cell Culture, Transduction, Plasmid Preparation, shRNA, Construct, Reverse Transcription Polymerase Chain Reaction, Transfection

Journal: Cancer Research Communications

Article Title: Age-Related Increases in IGFBP2 Increase Melanoma Cell Invasion and Lipid Synthesis

doi: 10.1158/2767-9764.CRC-23-0176

Figure Lengend Snippet: IGFBP2 increases melanoma cell migration and invasion. A, Wound healing assay of human melanoma cells (1205Lu, WM164) cultured with young or aged CM in the presence or absence of a neutralizing IGFBP2 antibody (5 mg/mL) or recombinant IGFBP2 (150 ng/mL). B, Matrigel invasion assay of melanoma cells (1205Lu, WM164) cultured with young and aged CM in the presence or absence of a neutralizing IGFBP2 antibody or recombinant IGFBP2. C, Melanoma cells (1205Lu) grown in 3D spheroids cultured with aged CM and young CM in the presence or absence of recombinant IGFBP2 (150 ng/mL) for 48 hours. GraphPad Prism 8 was used for plotting graphs and statistical analysis. Unpaired t test was performed.

Article Snippet: Tumors were allowed to grow, and treatment with rIgfbp2 (674-B2-025 from R&D Systems), Igfbp2-neutralizing antibody (AF674 from R&D Systems), or IgG control (AB-105-C from R&D Systems) was administered. rIGFBP2 experiments: young mice were injected intraperitoneally with 500 ng of rIgfbp2 in 100 μL of PBS every 2 days until tumors reach a maximum of 2,000 mm 3 .

Techniques: Migration, Wound Healing Assay, Cell Culture, Recombinant, Invasion Assay

Journal: Cancer Research Communications

Article Title: Age-Related Increases in IGFBP2 Increase Melanoma Cell Invasion and Lipid Synthesis

doi: 10.1158/2767-9764.CRC-23-0176

Figure Lengend Snippet: Igfbp2 increases melanoma tumor growth and metastasis in vivo . A, mCherry-tagged YUMM1.7 murine melanoma cells were grown in young (8 weeks old) C57BL6 mice. Tumor growth of young mice after i.p. treatment with 500 ng recombinant Igfbp2 or PBS (5 mice/group, treated i.p., 2 times a week, after tumors were palpable). B, IHC analysis of Igfbp2 in tumors from young mice treated with PBS or recombinant Igfbp2. C, Western blot analysis of tumor lysate from young mice treated with PBS and recombinant Igfbp2. Densitometry of phospho-AKT relative to HSP90 loading control. D, Tumor growth curve of YUMM1.7 melanoma cells subdermally injected in old (52 weeks old) mice treated i.p. with Igfbp2-neutralizing antibody (at a concentration of 1 mg/kg every day, n = 5) vs. an IgG control ( n = 5). E, IHC analysis of Igfbp2 staining in aged mice treated with either an IgG control or neutralizing Igfbp2 antibody. F, Protein expression analysis was performed on tumor lysate from aged mice treated with IgG or neutralizing Igfbp2 antibody. Quantification analysis of phospho-Akt and Fasn immunoblotting relative to Hsp90 loading control. G, Analysis of mCherry-positive cells in lungs of tumor-bearing aged mice treated with a neutralizing Igfbp2 antibody or IgG control. *, P < 0.05 student t test was used. GraphPad Prism 8 was used for plotting graphs and statistical analysis.

Article Snippet: Tumors were allowed to grow, and treatment with rIgfbp2 (674-B2-025 from R&D Systems), Igfbp2-neutralizing antibody (AF674 from R&D Systems), or IgG control (AB-105-C from R&D Systems) was administered. rIGFBP2 experiments: young mice were injected intraperitoneally with 500 ng of rIgfbp2 in 100 μL of PBS every 2 days until tumors reach a maximum of 2,000 mm 3 .

Techniques: In Vivo, Recombinant, Western Blot, Control, Injection, Concentration Assay, Staining, Expressing

Journal: Cell Death & Disease

Article Title: IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

doi: 10.1038/s41419-024-06843-y

Figure Lengend Snippet: RT-qPCR primers.

Article Snippet: The IGFBP2 levels in BLF and serum were measured using Human IGFBP2 ELISA kit (EHIGFBP2, Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.

Techniques:

Journal: Cell Death & Disease

Article Title: IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

doi: 10.1038/s41419-024-06843-y

Figure Lengend Snippet: The BLF ( n = 20) and blood samples ( n = 20) were collected from NSCLC patients. A The IGFBP2 level in BLF and serum was assessed by ELISA assay. B The mRNA level of IGFBP2 in lung tissues was detected by qRT-PCR. C The expression of IGFBP2 in NSCLC tissues based on TCGA database. D The immunoreactivity of IGFBP2 in lung tissues was detected by IHC analysis. E The secretion of IGFBP2 in culture medium was detected by ELISA assay. F , G The mRNA and protein levels of IGFBP2 were detected by qRT-PCR and western blot, respectively. In A , B , E , F, G , Student’s t -test. In C , Dunnett’s test of one-way ANOVA. * P < 0.05; ** P < 0.01; *** P < 0.005. BLF bronchoalveolar lavage fluid, TCGA The Cancer Genome Atlas.

Article Snippet: The IGFBP2 levels in BLF and serum were measured using Human IGFBP2 ELISA kit (EHIGFBP2, Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.

Techniques: Enzyme-linked Immunosorbent Assay, Quantitative RT-PCR, Expressing, Western Blot

Journal: Cell Death & Disease

Article Title: IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

doi: 10.1038/s41419-024-06843-y

Figure Lengend Snippet: NCI-H1650 and NCI-H1975 cells were either treated with 1 μg/mL human recombinant IGFBP2 (hr IGFBP2) or transfected with OE-IGFBP2/si-IGFBP2, followed by the treatment of gefitinib (10 nM). A Cell viability was monitored by CCK-8 assay. B Colony formation was detected by colony formation assay. C The scheme of the in vivo experiment design. Representative photos and in vivo imaging of xenograft tumors/lung metastases with quantitative analysis. The immunoreactivity of IGFBP2 in lung tissues was detected by IHC analysis. D The protein levels of N-cadherin and vimentin were detected by western blot. Dunnett’s test of one-way ANOVA. * P < 0.05; ** P < 0.01; *** P < 0.001. hr human recombinant, OE-NC overexpression vector alone, si-NC negative control siRNA.

Article Snippet: The IGFBP2 levels in BLF and serum were measured using Human IGFBP2 ELISA kit (EHIGFBP2, Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.

Techniques: Recombinant, Transfection, CCK-8 Assay, Colony Assay, In Vivo, In Vivo Imaging, Western Blot, Over Expression, Plasmid Preparation, Negative Control

Journal: Cell Death & Disease

Article Title: IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

doi: 10.1038/s41419-024-06843-y

Figure Lengend Snippet: Heatmap ( A ), GO ( B ) and KEGG enrichment pathway ( C ) and Reactome analysis ( D ) for RNA-seq. E Changes of GPCR signaling molecules were detected by sequencing. NCI-H1650 and NCI-H1975 cells were transfected with si- IGFBP2 or IGFBP2 overexpression construct. F , G The mRNA and protein levels of CXCL1 were detected by qRT-PCR and western blot, respectively. Dunnett’s test of one-way ANOVA. ** P < 0.01; *** P < 0.001. OE-NC overexpression vector alone, si-NC negative control siRNA.

Article Snippet: The IGFBP2 levels in BLF and serum were measured using Human IGFBP2 ELISA kit (EHIGFBP2, Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.

Techniques: RNA Sequencing Assay, Sequencing, Transfection, Over Expression, Construct, Quantitative RT-PCR, Western Blot, Plasmid Preparation, Negative Control

Journal: Cell Death & Disease

Article Title: IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

doi: 10.1038/s41419-024-06843-y

Figure Lengend Snippet: A , C The mRNA and protein levels of CXCL1 were detected by qRT-PCR and western blot, respectively. B The secretion of CXCL1 was detected by ELISA assay. D The immunoreactivity of CXCL1 in lung tissues was detected by IHC analysis. NCI-H1650 and NCI-H1975 cells were transfected with CXCL1 overexpression construct, si-CXCL1 or/and IGFBP2 overexpression construct. E Cell proliferation was monitored by CCK-8 assay. F Colony forming ability was assessed by colony formation assay with quantitative analysis. G , H Cell invasion and migration were detected by Transwell and wound healing assays with quantitative analysis, respectively. In A – C , Student’s t -test. In E – H , Dunnett’s test of one-way ANOVA. * P < 0.05; ** P < 0.01; *** P < 0.001. OE-NC, overexpression vector alone; si-NC, negative control siRNA.

Article Snippet: The IGFBP2 levels in BLF and serum were measured using Human IGFBP2 ELISA kit (EHIGFBP2, Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.

Techniques: Quantitative RT-PCR, Western Blot, Enzyme-linked Immunosorbent Assay, Transfection, Over Expression, Construct, CCK-8 Assay, Colony Assay, Migration, Plasmid Preparation, Negative Control

Journal: Cell Death & Disease

Article Title: IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

doi: 10.1038/s41419-024-06843-y

Figure Lengend Snippet: The interaction relation between IGFBP2 and ITGA5 through A BioGRID and B String databases. C , D The protein levels of ITGA5, STAT3, p-STAT3 and CXCL1 were detected by western blot.

Article Snippet: The IGFBP2 levels in BLF and serum were measured using Human IGFBP2 ELISA kit (EHIGFBP2, Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.

Techniques: Western Blot

Journal: Cell Death & Disease

Article Title: IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

doi: 10.1038/s41419-024-06843-y

Figure Lengend Snippet: NCI-H1650 or NCI-H1975 cells were transfected with IGFBP2 overexpression construct or/and si-ITGA5. A Colony formation was detected by colony formation assay. B , C Cell invasion and migration were measured by Transwell and wound healing assays with quantitative analysis, respectively. D The protein levels of N-cadherin and vimentin were detected by western blot. Dunnett’s test of one-way ANOVA. * P < 0.05; ** P < 0.01; *** P < 0.001. OE-NC overexpression vector alone, si-NC negative control siRNA.

Article Snippet: The IGFBP2 levels in BLF and serum were measured using Human IGFBP2 ELISA kit (EHIGFBP2, Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.

Techniques: Transfection, Over Expression, Construct, Colony Assay, Migration, Western Blot, Plasmid Preparation, Negative Control

Journal: Cell Death & Disease

Article Title: IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

doi: 10.1038/s41419-024-06843-y

Figure Lengend Snippet: A The putative interaction between IGFBP2 and ITGA5 was validated by yeast two hybrid assay. B The interaction between IGFBP2 and ITGA5 in lung metastases and NSCLC cells was detected by co-IP. Whole cell lysates or normal IgG served as an input or negative control, respectively. C The in vitro binding of GST-tagged IGFBP2 and His-tagged ITGA5 was assessed by GST pull-down assay.

Article Snippet: The IGFBP2 levels in BLF and serum were measured using Human IGFBP2 ELISA kit (EHIGFBP2, Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.

Techniques: Y2H Assay, Co-Immunoprecipitation Assay, Negative Control, In Vitro, Binding Assay, Pull Down Assay

Journal: Cell Death & Disease

Article Title: IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

doi: 10.1038/s41419-024-06843-y

Figure Lengend Snippet: A The scheme of the in vivo experiment design. Representative photos of lung metastases with quantitative analysis and in vivo imaging of lung tissues. The immunoreactivities of IGFBP2, STAT3 and CXCL1 in lung metastases were detected by IHC analysis. Dunnett’s test of one-way ANOVA. * P < 0.05; ** P < 0.01; *** P < 0.001.

Article Snippet: The IGFBP2 levels in BLF and serum were measured using Human IGFBP2 ELISA kit (EHIGFBP2, Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.

Techniques: In Vivo, In Vivo Imaging

Journal: Cell Death & Disease

Article Title: IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

doi: 10.1038/s41419-024-06843-y

Figure Lengend Snippet: IGFBP2/ITGA5 promoted gefitinib resistance via activating STAT3/CXCL1 axis.

Article Snippet: The IGFBP2 levels in BLF and serum were measured using Human IGFBP2 ELISA kit (EHIGFBP2, Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.

Techniques: